Investors in the stock market know that stocks yo-yo all the time. Sometimes, the yo-yoing becomes so severe it could trigger the soaring of some stocks and the tumbling of others.
This article is about the plummeting of the biotech stocks.
Small development-stage biotech stocks, more than stocks belonging to other industries are subjected to a shredding of their values. Some would lose more than 80% of their prices, others would lose a little less or more, which is still devastates their shareholders.
Being or not shareholders of plummeted stock, how investors should act differently . . .